S. Teranishi

Identification of Biomarkers for Non–small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor

Keisuke Watanabe, Y. Hara, T. Kaneko, 2020, AntiCancer Research.

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial

N. Horita, Keisuke Watanabe, Y. Hara, 2021, Thoracic cancer.

MicroRNA‐200b is a potential biomarker of the expression of PD‐L1 in patients with lung cancer

N. Horita, Keisuke Watanabe, Y. Hara, 2020, Thoracic cancer.

Identification of a novel biomarker based on lymphocyte count, albumin level, and TBAg/PHA ratio for differentiation between active and latent tuberculosis infection in Japan.

Keisuke Watanabe, Y. Hara, T. Kaneko, 2020, Tuberculosis.

Retrospective analysis of independent predictors of progression‐free survival in patients with EGFR mutation‐positive advanced non‐small cell lung cancer receiving first‐line osimertinib

T. Kaneko, Masaki Yamamoto, N. Kobayashi, 2022, Thoracic cancer.

Reproducibility of the T-SPOT.TB test for screening Mycobacterium tuberculosis infection in Japan.

T. Kaneko, Masaki Yamamoto, N. Kobayashi, 2020, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

T‐cell response to phytohemagglutinin in the interferon‐γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non‐small cell lung cancer

N. Horita, Keisuke Watanabe, Y. Hara, 2021, Thoracic cancer.

Class A CpG oligodeoxynucleotide inhibits IFN‐γ‐induced signaling and apoptosis in lung cancer

T. Kaneko, Masaki Yamamoto, Y. Shibata, 2020, Thoracic cancer.